| Articles | 
									
										
		  							 | 
          							
		  									  								 
		  									  							    
		  									  								 
		  									  							 | 
        						 
      						 
      					 | 
  					 
  					
    					 | 
   					 
   										
    					| Prognostic value of human papillomavirus 16/18 genotyping in low-grade cervical lesions preceded by mildly abnormal cytology | 
  					 
  					  										
						| Jing Ye, Bei Cheng, Yi-fan Cheng, Ye-li Yao, Xing Xie, Wei-guo Lu, Xiao-dong Cheng | 
					 
															
						| Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China | 
					 
										
						 | 
					 
				 
				
				
					
						
							
								
									
									
									
									
									 
          
          
            
              
				
												  
													
													    | 
													    	
														 | 
													 
												
													
													
														
															
													     		                            						                            																	     
														Abstract  Histological low-grade squamous intraepithelial lesion/cervical intraepithelial neoplasia grade 1 (LSIL/CIN1) preceded by normal or mildly abnormal cytology is recommended for conservative follow-up, with no separated management. In this study, we assessed the triage value of human papillomavirus (HPV) 16/18 genotyping in 273 patients with LSIL/CIN1. HPV16/18 genotyping was performed at baseline and follow-up was at 6-monthly intervals for up to 2 years. At each follow-up, women positive for cytology or high-risk HPV (hrHPV) were referred for colposcopy. Enrollment cytology, HPV16/18 genotyping, and questionnaire-obtained factors were linked to the 2-year cumulative progression rate. Univariate and multivariate analyses were performed taking into account time-to-event with Cox proportional hazard regression. The results showed that 190 cases (69.6%) regressed, 37 (13.6%) persisted, and 46 (16.8%) progressed. HPV16/18 positivity (hazard ratio (HR), 2.708; 95% confidence interval (CI), 1.432–5.121; P=0.002) is significantly associated with higher 2-year cumulative progression rate. Sub-analysis by enrollment cytology and age restricted the positive association among patients preceded by mildly abnormal cytology and aged 30 years or older. Immediate treatment is a rational recommendation for the high-risk subgroup, when good compliance is not assured.
														
  
																										     | 
														 
																											
												  		
														
															| 
															    																	Received: 17 October 2016
																	    
															    															    															    																	Published: 08 March 2017
															    															 | 
														 
														 														
															| 
																
															 | 
														 
																																									    																											 
												 
												
												
												
												
									
									 
												
             
                                   			 
			 
             
												
											    	
											        	 | 
											        	Viewed | 
											         
													
											        	 | 
											        	 | 
											         
											      	
												         | 
												        
												        	Full text 
												          	
												         | 
											        	
												        	
												        	 
												        	
												          	 
												          	
												          	
														 | 
													 
													
												         | 
												         | 
													 
													
												         | 
												        
												        	Abstract 
												          	
														 | 
												        
															
															 
															
															
												         | 
													 
													
												         | 
												         | 
													 
													
												         | 
												        Cited  | 
												        
												        	
												         | 
													 
													
												         | 
												         | 
												         | 
													 
													
													    |   | 
													    Shared | 
													       | 
												  	 
												  	
													     | 
													     | 
													     | 
											  		 
											  		
													    |   | 
													    Discussed | 
													       | 
												  	 
											 
											 
             
           
      
									
									
		
									
									
									
									
									
									 | 
								 
							 
						 | 
					 
				 
			
		 |